Login
Home
Charts
Search
Watchlist
Products

Alkyl Amines Chemicals Ltd

ALKYLAMINE·NSE
1,863.80-0.22%Tue, 22 Sept '26

Alkyl Amines Chemicals Ltd

ALKYLAMINE
NSE
1,863.80
-0.22%
|Tue, 22 Sept '26
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
9,533Cr
Close
Close Price
1,863.80
Industry
Industry
Speciality Chemicals
PE
Price To Earnings
42.33
PS
Price To Sales
5.75
Revenue
Revenue
1,658Cr
Rev Gr TTM
Revenue Growth TTM
5.11%
PAT Gr TTM
PAT Growth TTM
20.63%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
352322357400415371386406389354387528
Growth YoY
Revenue Growth YoY%
-13.8-17.1-13.5-2.517.815.38.31.5-6.1-4.60.230.2
Expenses
ExpensesCr
304262288321341301318329319287316394
Operating Profit
Operating ProfitCr
4860697974716877706771134
OPM
OPM%
13.718.519.319.817.719.017.618.918.019.018.325.3
Other Income
Other IncomeCr
253597987889
Interest Expense
Interest ExpenseCr
211000000000
Depreciation
DepreciationCr
131717181818181818181818
PBT
PBTCr
3646536664595966595761125
Tax
TaxCr
91315171715131716151530
PAT
PATCr
273338494744464943424595
Growth YoY
PAT Growth YoY%
-48.0-26.9-20.9-1.874.230.919.71.2-9.5-3.4-1.491.4
NPM
NPM%
7.710.410.812.211.411.811.912.211.011.911.717.9
EPS
EPS
5.36.57.59.69.38.69.09.78.48.38.918.5
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
352322357400415371386406389354387528
Growth YoY
Revenue Growth YoY%
-13.8-17.1-13.5-2.517.815.38.31.5-6.1-4.60.230.2
Expenses
ExpensesCr
304262288321341301318329319287316394
Operating Profit
Operating ProfitCr
4860697974716877706771134
OPM
OPM%
13.718.519.319.817.719.017.618.918.019.018.325.3
Other Income
Other IncomeCr
253597987889
Interest Expense
Interest ExpenseCr
211000000000
Depreciation
DepreciationCr
131717181818181818181818
PBT
PBTCr
3646536664595966595761125
Tax
TaxCr
91315171715131716151530
PAT
PATCr
273338494744464943424595
Growth YoY
PAT Growth YoY%
-48.0-26.9-20.9-1.874.230.919.71.2-9.5-3.4-1.491.4
NPM
NPM%
7.710.410.812.211.411.811.912.211.011.911.717.9
EPS
EPS
5.36.57.59.69.38.69.09.78.48.38.918.5

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
4845016168469931,2421,5421,6831,4411,5721,5361,658
Growth
Revenue Growth%
1.53.523.137.417.325.124.19.2-14.49.1-2.35.1
Expenses
ExpensesCr
3934065006827368131,2171,3391,1901,2811,2511,317
Operating Profit
Operating ProfitCr
9195116164257429325344251291285342
OPM
OPM%
18.819.018.919.425.934.521.120.417.418.518.520.6
Other Income
Other IncomeCr
2134407151315303233
Interest Expense
Interest ExpenseCr
88815106334111
Depreciation
DepreciationCr
131416232729354559717272
PBT
PBTCr
727496130260401302309202249243302
Tax
TaxCr
2324314644105778054636377
PAT
PATCr
50506484215295225229149186180225
Growth
PAT Growth%
9.81.027.730.3157.137.2-23.91.7-34.925.0-3.320.6
NPM
NPM%
10.310.110.49.921.723.814.613.610.311.811.713.6
EPS
EPS
9.89.912.616.442.223.244.044.829.136.435.244.0
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
4845016168469931,2421,5421,6831,4411,5721,5361,658
Growth
Revenue Growth%
1.53.523.137.417.325.124.19.2-14.49.1-2.35.1
Expenses
ExpensesCr
3934065006827368131,2171,3391,1901,2811,2511,317
Operating Profit
Operating ProfitCr
9195116164257429325344251291285342
OPM
OPM%
18.819.018.919.425.934.521.120.417.418.518.520.6
Other Income
Other IncomeCr
2134407151315303233
Interest Expense
Interest ExpenseCr
88815106334111
Depreciation
DepreciationCr
131416232729354559717272
PBT
PBTCr
727496130260401302309202249243302
Tax
TaxCr
2324314644105778054636377
PAT
PATCr
50506484215295225229149186180225
Growth
PAT Growth%
9.81.027.730.3157.137.2-23.91.7-34.925.0-3.320.6
NPM
NPM%
10.310.110.49.921.723.814.613.610.311.811.713.6
EPS
EPS
9.89.912.616.442.223.244.044.829.136.435.244.0

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
1010101010101010101010
Reserves
ReservesCr
1892352873555267829801,1591,2571,3921,523
Current Liabilities
Current LiabilitiesCr
131161180248154282328354227245216
Non Current Liabilities
Non Current LiabilitiesCr
761061601369371546989141146
Total Liabilities
Total LiabilitiesCr
4065126377497831,1451,3711,5921,5841,7891,895
Current Assets
Current AssetsCr
184225238311294528538501443630673
Non Current Assets
Non Current AssetsCr
2232873994384896178341,0911,1401,1591,223
Total Assets
Total AssetsCr
4065126377497831,1451,3711,5921,5841,7891,895
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
1010101010101010101010
Reserves
ReservesCr
1892352873555267829801,1591,2571,3921,523
Current Liabilities
Current LiabilitiesCr
131161180248154282328354227245216
Non Current Liabilities
Non Current LiabilitiesCr
761061601369371546989141146
Total Liabilities
Total LiabilitiesCr
4065126377497831,1451,3711,5921,5841,7891,895
Current Assets
Current AssetsCr
184225238311294528538501443630673
Non Current Assets
Non Current AssetsCr
2232873994384896178341,0911,1401,1591,223
Total Assets
Total AssetsCr
4065126377497831,1451,3711,5921,5841,7891,895

Cash Flow

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
10163102144189364205248275263239
Investing Cash Flow
Investing Cash FlowCr
-35-65-132-67-41-213-206-277-121-196-137
Financing Cash Flow
Financing Cash FlowCr
-68-232-60-136-86-578-140-49-56
Net Cash Flow
Net Cash FlowCr
-2-32171265-58-21131845
Free Cash Flow
Free Cash FlowCr
66-1-3375111208-41-55153216111
CFO To PAT
CFO To PAT%
203.4126.0158.0172.287.6123.291.0108.6184.6141.4132.5
CFO To EBITDA
CFO To EBITDA%
111.466.787.387.773.484.863.072.2109.790.483.8
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
10163102144189364205248275263239
Investing Cash Flow
Investing Cash FlowCr
-35-65-132-67-41-213-206-277-121-196-137
Financing Cash Flow
Financing Cash FlowCr
-68-232-60-136-86-578-140-49-56
Net Cash Flow
Net Cash FlowCr
-2-32171265-58-21131845
Free Cash Flow
Free Cash FlowCr
66-1-3375111208-41-55153216111
CFO To PAT
CFO To PAT%
203.4126.0158.0172.287.6123.291.0108.6184.6141.4132.5
CFO To EBITDA
CFO To EBITDA%
111.466.787.387.773.484.863.072.2109.790.483.8

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
6409191,2351,7112,45711,61614,60611,0259,2698,2706,2989,533
Price To Earnings
Price To Earnings
12.918.319.220.411.439.465.048.362.344.535.042.3
Price To Sales
Price To Sales
1.31.82.02.02.59.39.56.56.45.34.15.8
Price To Book
Price To Book
3.23.84.24.74.614.714.89.47.35.94.16.2
EV To EBITDA
EV To EBITDA
8.110.711.911.19.626.944.832.336.927.721.427.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
32.632.331.631.538.147.032.433.330.332.132.532.5
OPM
OPM%
18.819.018.919.425.934.521.120.417.418.518.520.6
NPM
NPM%
10.310.110.49.921.723.814.613.610.311.811.713.6
ROCE
ROCE%
27.123.723.229.346.148.530.224.816.317.715.915.9
ROE
ROE%
25.020.521.622.940.137.322.719.611.813.311.711.7
ROA
ROA%
12.39.810.111.227.525.816.414.49.410.49.59.5
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
6409191,2351,7112,45711,61614,60611,0259,2698,2706,2989,533
Price To Earnings
Price To Earnings
12.918.319.220.411.439.465.048.362.344.535.042.3
Price To Sales
Price To Sales
1.31.82.02.02.59.39.56.56.45.34.15.8
Price To Book
Price To Book
3.23.84.24.74.614.714.89.47.35.94.16.2
EV To EBITDA
EV To EBITDA
8.110.711.911.19.626.944.832.336.927.721.427.4
Profitability Ratios
Profitability Ratios
GPM
GPM%
32.632.331.631.538.147.032.433.330.332.132.532.5
OPM
OPM%
18.819.018.919.425.934.521.120.417.418.518.520.6
NPM
NPM%
10.310.110.49.921.723.814.613.610.311.811.713.6
ROCE
ROCE%
27.123.723.229.346.148.530.224.816.317.715.915.9
ROE
ROE%
25.020.521.622.940.137.322.719.611.813.311.711.7
ROA
ROA%
12.39.810.111.227.525.816.414.49.410.49.59.5
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Alkyl Amines Chemicals Ltd is a four-decade-old Indian manufacturer that makes the invisible chemical building blocks other industries cannot do without - aliphatic amines and their derivatives, the intermediates that go into pharmaceuticals, crop-protection chemicals, water-treatment and rubber products. Founded in 1979 by the Kothari family and still led by its Chairman and Managing Director, the company has grown from a single site to three integrated plants in Maharashtra and Gujarat, exporting to 39 countries while remaining a single-entity, zero-subsidiary business. Its recurring approach is to bet big on in-house process technology, build world-scale capacity ahead of demand, and then defend that position through quality consistency and anti-dumping protection - a philosophy that explains both its commissioning of the world’s largest ethylamines plant and its modest self-definition as an intermediates company, not a specialty-chemicals player. # Business segments A single engine - aliphatic amines and their derivatives - sold as intermediates to industrial customers across pharmaceuticals, agrochemicals, water treatment and rubber chemicals, manufactured at three integrated sites and supported by captive solar power and an in-house R&D centre. ## 1. Amines and derivatives: the chemical intermediates engine **The company makes roughly 30 amine-based products, sells them to other manufacturers as raw-material inputs, and earns on every kilogram shipped - a pure B2B intermediates business where scale, process know-how and trade protection set the winners apart.** - **Three product families, one chemistry** - the portfolio splits into aliphatic amines (about 45% of turnover), amine derivatives (about 31%) and other specialty chemicals (about 25%), all built on the same ammonia-based chemistry that gives the company its name. - **World-scale ethylamines plant** - the Kurkumbh facility houses the single largest ethylamine plant in the world at 100 tons per day, commissioned in late 2023 and fully operational by February 2024, representing a ₹400-crore bet on domestic and export demand. - **Dedicated plants, not flexible batch reactors** - each product runs on its own dedicated equipment, which makes it hard for competitors to refurbish existing assets and enter the market, creating a natural barrier to entry. - **Acetonitrile: first-mover with a quality moat** - the 18,000-ton acetonitrile plant at Dahej took years of trial and error to get product quality right, so even though building the hardware is not technically difficult, replicating the output is; an anti-dumping duty was levied in June 2025 to counter Chinese imports. - **Captive consumption feeds the merchant business** - about 30% of methylamines produced are used in-house to make derivatives, while 70% is sold to outside customers, giving the company both a cost advantage on derivatives and a presence in the merchant market. ## 2. The customer and revenue model: transactional B2B sales, mostly domestic **Every rupee comes from selling chemical intermediates to industrial buyers - roughly 80% in India and 20% exported - with prices set by market forces and raw-material costs passed through where possible.** - **Direct sales plus a dealer network** - the company sells straight to industrial customers and through 150 dealers and distributors, with the top 10 dealers accounting for about two-thirds of dealer sales. - **Market-driven pricing with some pass-through** - since all major competitors use similar technology and cost structures, prices are set by the market; when raw-material costs rise, the company can partially reflect that in higher product prices. - **Anti-dumping as a competitive tool** - the company actively files for anti-dumping investigations when cheap imports, particularly from China, threaten its market share, as it did successfully for acetonitrile and is pursuing for monoisopropylamine. ## 3. Manufacturing and supply chain: three integrated sites with captive energy **Production runs across three Maharashtra and Gujarat plants, each with zero-liquid-discharge capability, supported by three company-owned solar farms that feed electricity back to the factories.** - **Three-site footprint** - Patalganga and Kurkumbh in Maharashtra, and Dahej in Gujarat, form the manufacturing backbone, with a swing plant at Patalganga that can switch between ethyl and methyl amines depending on demand. - **Solar power cuts the energy bill** - three solar plants totalling at least 8.5 MW supply electricity to the manufacturing sites, with the Bhoom plant dedicated to Kurkumbh and the Talegadh plant in Gujarat commissioned in January 2024. - **Raw-material vulnerability is real** - ammonia, acetic acid, ethyl alcohol and petroleum-based alcohols are the critical inputs; a Middle East geopolitical disruption in March 2026 triggered a force majeure on ammonia supply, temporarily suspending ammonia-based production at all three sites. # Group structure and partners **The company is a standalone listed entity with no subsidiaries, no joint ventures and no associate companies - everything runs through the single balance sheet.** - The entire business is conducted through Alkyl Amines Chemicals Ltd alone; consolidated financial statements are not prepared because there is nothing to consolidate. - The Board has 10 members including two women, and the six key managerial personnel include the Chairman and Managing Director, two Executive Directors and a Whole-time Director of Operations. - The company participates in the Indian Chemical Council’s Responsible Care® programme, with certification valid until October 2026, and is a member of Nicer Globe for transport safety.

Documents — Alkyl Amines Chemicals Ltd

  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/svffgg375yc7th1vbc2twcg9.pdf
  • Q2 FY2026 Earnings Call Transcript (Sep 2025, PDF): https://www.stockscans.in/document/soddkaid87nvx0a38m16ooi0.pdf
  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/4msutg7qnlyvowupvp6uw2ok.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/cxzrn4htxschmohzu0lamzy4.pdf
  • Q4 FY2024 Earnings Call Transcript (Mar 2024, PDF): https://www.stockscans.in/document/20ozqc3jausfw7c70tbxciw7.pdf
  • Q2 FY2024 Earnings Call Transcript (Sep 2023, PDF): https://www.stockscans.in/document/3sm9wxyd7iwqphhu9t51dc2o.pdf
  • Q4 FY2023 Earnings Call Transcript (Mar 2023, PDF): https://www.stockscans.in/document/oer6ctlojq95g7dyt4wg7lm8.pdf
  • Q2 FY2023 Earnings Call Transcript (Sep 2022, PDF): https://www.stockscans.in/document/9k037e3w7lcv1oshmncv0gvb.pdf
  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/xphl1702iev5m43wub1yp999.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/lffiqks24pqja75e5ac926lq.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/j9b6ok8wov1wjodwgf2hpub4.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/ceq9g80l8lzybon28foari7t.pdf
  • Q1 FY2026 Quarterly Result (Jun 2025, PDF): https://www.stockscans.in/document/mw3s2r1kjyy731irep7h1its.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/nvm7hv58dn0bgbbra4fdzy2m.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/k3se51efua9jdkwiaoifazcm.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/riwocyko2fxobanhtd4kvh30.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/logcptdk3990nvfgpaqm9gjy.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/dfktzy07mn76js33cx007o2g.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/c0wgxrltif3ifpbzhujnucka.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/aqn08aju3klvdpiuxs4is2a5.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/3xjkgvz5mupplyu5vlvdeaqz.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/aue8u8j0oyz52l85gftw3f9h.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/itzt63bb2773nqmz6ec3su2t.pdf

Concall Transcript Summaries — Alkyl Amines Chemicals Ltd

  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3AALKYLAMINE/transcript-notes/202603/svffgg375yc7th1vbc2twcg9.pdf
  • Q2 FY2026 Concall Transcript Summary (Sep 2025): https://www.stockscans.in/company/NSE%3AALKYLAMINE/transcript-notes/202509/soddkaid87nvx0a38m16ooi0.pdf
  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3AALKYLAMINE/transcript-notes/202503/4msutg7qnlyvowupvp6uw2ok.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3AALKYLAMINE/transcript-notes/202409/cxzrn4htxschmohzu0lamzy4.pdf
  • Q4 FY2024 Concall Transcript Summary (Mar 2024): https://www.stockscans.in/company/NSE%3AALKYLAMINE/transcript-notes/202403/20ozqc3jausfw7c70tbxciw7.pdf
  • Q2 FY2024 Concall Transcript Summary (Sep 2023): https://www.stockscans.in/company/NSE%3AALKYLAMINE/transcript-notes/202309/3sm9wxyd7iwqphhu9t51dc2o.pdf
  • Q4 FY2023 Concall Transcript Summary (Mar 2023): https://www.stockscans.in/company/NSE%3AALKYLAMINE/transcript-notes/202303/oer6ctlojq95g7dyt4wg7lm8.pdf
  • Q2 FY2023 Concall Transcript Summary (Sep 2022): https://www.stockscans.in/company/NSE%3AALKYLAMINE/transcript-notes/202209/9k037e3w7lcv1oshmncv0gvb.pdf